Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
On January 28, 2026, Obagi Medical announced a significant collaboration with Next Health as part of its ALOHA Program, focusing on the evaluation of the Obagi® saypha® MagIQ™ hyaluronic acid filler. This partnership aims to create real-world evidence regarding the efficacy of Obagi's products in wellness-oriented settings. Next Health, known for its innovative approach to personalized wellness and aesthetic treatments, will conduct a multi-site assessment of saypha® MagIQ™ across its network of health optimization centers.
Dr. Milan Shah, Next Health's Director of Aesthetics, emphasized the synergy between the ALOHA Program and Next Health’s mission to enhance longevity and aesthetic outcomes through evidence-based practices. The initiative will not only examine clinical efficacy but also assess patient experiences, aiming to improve satisfaction and loyalty among providers and clients alike.
The ALOHA Program will standardize the data collection process across participating Next Health locations, with preliminary findings set to be shared at leadership meetings and major industry conferences. This effort seeks to showcase the performance of saypha® MagIQ™ in the realm of longevity and optimization.
Drew Fine, U.S. General Manager of Obagi’s Professional Channel, highlighted the partnership's role in advancing aesthetic solutions supported by robust scientific evidence. Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, features proprietary MACRO Core Technology, ensuring stable results and high efficacy.
Obagi Medical, with over 35 years in the skincare industry, focuses on innovative solutions addressing various skin concerns. Meanwhile, Next Health, established in 2016, is at the forefront of health optimization, offering cutting-edge treatments to promote longevity. This collaboration exemplifies a commitment to merging aesthetic enhancements with holistic wellness strategies.
MWN-AI** Analysis
The recent collaboration between Obagi Medical, a prominent player in the skincare industry, and Next Health represents a strategic move to enhance market positioning and drive innovation through the ALOHA Program. This initiative aims to generate robust real-world evidence for Obagi's Hyaluronic Acid filler, saypha® MagIQ™, leveraging Next Health's expertise in aesthetics and wellness optimization.
Market analysts should view this partnership positively. By integrating Obagi's high-performance injectables with Next Health’s holistic, evidence-based treatment protocols, the collaboration is likely to position both companies as leaders in the evolving wellness and aesthetics spaces. The program’s focus on clinical efficacy and patient experience can drive patient satisfaction and foster client loyalty, which are critical in the competitive skincare market.
Investors should take note of Obagi's strong historical performance, particularly its status as the fastest-growing professional skincare brand in the U.S. as of 2024. The innovative MACRO Core Technology behind saypha® MagIQ™, designed for predictable and natural-looking results, further emphasizes Obagi's commitment to research-driven solutions.
Moreover, with demand growing for personalized wellness and anti-aging treatments, Obagi's alliance with Next Health places it at the forefront of a trend that prioritizes comprehensive care. This proactive approach is likely to generate valuable insights that not only improve patient outcomes but can also yield marketing advantages through data-driven storytelling.
In summary, investors might consider monitoring Obagi's stock performance closely, particularly as initial findings from the ALOHA Program emerge in industry conferences. The collaboration not only bolsters Obagi's innovative offerings but enhances its reputation within the rapidly expanding wellness sector, positioning it favorably for future growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Next Health as a key partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Next Health was selected for its pioneering commitment to longevity, personalized wellness, and cutting-edge aesthetic treatments across its growing network of health optimization centers.
Through this real-world evaluation collaboration, Next Health will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ within its practices. The program will leverage Next Health’s expertise in integrating advanced injectables with holistic protocols, patient-centric education, and data-driven outcomes to generate meaningful real-world evidence on the filler’s performance in wellness-focused environments.
“At Next Health, we’re dedicated to pushing the boundaries of longevity and aesthetic medicine through innovative, evidence-based approaches,” said Dr. Milan Shah, Director of Aesthetics at Next Health. “Obagi’s ALOHA Program aligns perfectly with our mission to deliver transformative results by combining high-performance injectables like saypha® MagIQ™ with comprehensive skincare and wellness strategies. This partnership allows us to contribute real-world insights that elevate patient care and outcomes across our network.”
The ALOHA Program evaluates both clinical efficacy and patient experience while equipping providers with integrated Obagi protocols to enhance satisfaction, loyalty, and consistent results. Standardized data will be collected across participating Next Health locations, with initial findings to be shared at upcoming Next Health leadership meetings and presented at major industry conferences to showcase the impact of this new injectable in a longevity and optimization setting.
“Collaborating with forward-thinking leaders like Next Health reinforces Obagi’s dedication to launching aesthetics solutions supported by robust, practice-based evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program with Next Health highlights our shared vision of holistic care—bridging injectables and skincare to drive superior patient results and practice growth in the evolving wellness landscape.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Next Health
Founded in 2016 by Dr Darshan Shah, cofounded by Kevin Peake, and where Dr Milan Shah has since served on the Medical Advisory Board, Next Health is a leading Health Optimization and Longevity Center dedicated to helping individuals live healthier, longer lives through personalized, cutting-edge treatments. Offering services such as IV therapy, regenerative aesthetics, hormone optimization, and advanced diagnostics, Next Health operates a growing network of state-of-the-art wellness centers focused on vitality, performance, and evidence-based care. For more information, visit www.next-health.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between Obagi Medical and Next Health, as part of the Waldencast Acquisition Corp. WALD, impact the aesthetic treatment landscape in cities like New York compared to Los Angeles?
What specific metrics will be utilized in the ALOHA Program to evaluate the effectiveness of Obagi's saypha® MagIQ™ across different demographics in New York versus Los Angeles under the Waldencast Acquisition Corp. WALD initiative?
In what ways do consumer preferences for skincare and aesthetic treatments differ between New York and Los Angeles, and how might these insights shape Waldencast Acquisition Corp. WALD’s marketing strategy for Obagi Medical’s offerings?
Given the rise of wellness-focused environments in major cities, how does the collaboration between Obagi Medical and Next Health reflect broader trends in patient care and satisfaction in New York and Los Angeles under Waldencast Acquisition Corp. WALD?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-4.69% G/L:
$1.525 Last:
13,064 Volume:
$1.51 Open:
